ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/AKT
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/AKT
5
trial(s) found.
NCT06533059
Advanced
Phase 1
Recruiting
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients With Advanced Solid Tumors With AKT1 E17K Mutation (
2618-001
)
AKT1 E17K inhibitor
Breast cancer
Endometrial cancer
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05563220
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (
ELEVATE
)
selective estrogen receptor degrader
+ AKT inhibitor
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NCT04862663
Advanced
Phase 3
Recruiting
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (
CAPItello-292
)
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)
2228 - Miranda - Southside Cancer Care Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
+ AKT inhibitor
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ AKT inhibitor
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Recruitment Country and State
WA (4)
NSW (3)
VIC (3)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 3 (1)
Trial Type
Advanced (5)
Cancer Therapy Class
AKT
100%
CDK4
80%
CDK6
80%
ER
80%
oestrogen axis
80%
PI3Kalpha
60%
mTOR
40%
mTORC1
40%
ERBB2
40%
PD-1/PD-L1
40%
PD-L1
40%
CDK7
20%
CD40
20%
IL-6
20%
LIV1
20%
Trop2
20%
VEGF
20%
Facility
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2031 - Randwick - Prince of Wales Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2109 - North Ryde - Macquarie University Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Endometrial cancer
Gynaecological cancer
Breast adenocarcinoma
ER-positive breast cancer
HR-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy